The Event Engine
Detect material changes. Verify the evidence. Deliver event intelligence.
From authoritative records to verified events.
The Event Engine continuously monitors mapped sources, detects material changes, verifies the evidence and preserves a traceable event record.
AXL Atlas
Maps sources, event types, relationships, materiality rules and required evidence.
Change Models
Compares current records with prior states and historical patterns to identify meaningful deviations.
Evidence Verification
Checks supporting sources, flags conflicts and preserves the evidence, timestamp and correction history behind each event.
| Entities | 412 |
| Claims | 288 |
| Commitments | 196 |
| Events | 243 |
| States | 167 |
| Outcomes | 106 |
- Third move on primary completion date in 14 months
- Corvane slipped 4 of its last 6 phase 3 trials
- Enrollment figure unchanged for 9 months
- Two sites removed in the same revision
| Field | Primary completion date |
| Source | Registry record v7 |
| Checked | 14 May, 09:41 ET |
| Corrected | 14 May, 09:44 ET |
| Scores | On readout |
Real-time news, analytics, forecasts, indexes and resolution all run on the same verified event record.
Signals
Corvane pushes CVN‑401 phase 3 completion to September
The second-line lung cancer trial’s primary completion date moved from 15 March to 30 September 2026, six months later than filed.
Third slip in 14 months. Four of Corvane’s last six phase 3 trials have moved.
Indicators
Share of active phase 3 trials whose primary completion date moved in the trailing 90 days.
Forecasts
Resolutions
14 Apr 2027
Meridian’s MRD‑217 approved three days early. Label restricted to second-line use.